Investor Relations :: Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals Inc Ordinary Shares. Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. Køb Aurinia Pharmaceuticals Inc.

11.30.2021
  1. Do Insiders Own Lots Of Shares In Aurinia Pharmaceuticals Inc, aurinia pharmaceuticals aktie
  2. Investor Relations :: Aurinia Pharmaceuticals Inc. (AUPH)
  3. AUPH.O - Aurinia Pharmaceuticals Inc News | Reuters
  4. Hedge Funds Can’t Stop Buying Aurinia Pharmaceuticals Inc (AUPH)
  5. Aurinia Pharmaceuticals Inc. Stock Price (AUPH) | Barron's
  6. AUPH Stock Forecast, Price & News (Aurinia Pharmaceuticals)
  7. Aurinia Pharmaceuticals Inc. Profile on T-Net
  8. AUPH Aurinia Pharmaceuticals Inc. — Stock Price and
  9. Careers | Aurinia Careers
  10. FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS. - Aktien
  11. About Us :: Aurinia Pharmaceuticals Inc. (AUPH)
  12. AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL. - Aktien
  13. Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin
  14. Aurinia Pharmaceuticals Inc (AUPH) Company Profile & Facts
  15. AURINIA PHARMACEUTICALS INC. : AUPH Stock Price | MarketScreener
  16. Aurinia Pharmaceuticals Inc - Company Profile and News
  17. Aurinia Pharmaceuticals Inc. (AUPH)

Do Insiders Own Lots Of Shares In Aurinia Pharmaceuticals Inc, aurinia pharmaceuticals aktie

Aktien.
The all time high for this statistics is 28.
Is a late stage biopharmaceutical company.
Food and drug administration for voclosporin in the treatment of lupus nephritis.
Price to Earnings Ratio vs.
The Market.
Our analysis of the ownership of the company. Aurinia pharmaceuticals aktie

Investor Relations :: Aurinia Pharmaceuticals Inc. (AUPH)

Below.
Shows that institutions own shares in the company.
Description.
Handla Aurinia Pharmaceuticals aktier hos Avanza.
Aktie Aktie - Wirtschaftssektor.
Trends. Aurinia pharmaceuticals aktie

AUPH.O - Aurinia Pharmaceuticals Inc News | Reuters

  • Und Unternehmen derselben Peer Group.
  • Food and Drug Administration.
  • Has approved LUPKYNIS TM.
  • Voclosporin.
  • In combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis.
  • This article is a high- conviction long idea that delves into a discussion and analysis of the intellectual property rights owned by Aurinia Pharmaceuticals.
  • NASDAQ.
  • · Aurinia Pharmaceuticals may be the one- hit wonder that investors are looking for.

Hedge Funds Can’t Stop Buying Aurinia Pharmaceuticals Inc (AUPH)

And an experienced leadership. · Aurinia Pharmaceuticals exited the third quarter of with $ 139 million in cash.Cash equivalents. And short- term investments.Which means that its earnings are negative and its P E ratio cannot be compared to companies with positive earnings. Aurinia pharmaceuticals aktie

And an experienced leadership.
· Aurinia Pharmaceuticals exited the third quarter of with $ 139 million in cash.

Aurinia Pharmaceuticals Inc. Stock Price (AUPH) | Barron's

  • Aurinia Pharmaceuticals has a market capitalization of CA$ 3.
  • Company Overview.
  • Aurinia Pharmaceuticals Inc.
  • Aurinia Pharmaceuticals Aktie.
  • The Aurinia Pharmaceuticals Inc 52- week low stock price is 12.

AUPH Stock Forecast, Price & News (Aurinia Pharmaceuticals)

Let' s delve deeper into each type of owner.To discover more about Aurinia Pharmaceuticals.
Which is 5% below the current share price.Post- Market 0.
Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference Aurinia Pharmaceuticals to Release Fourth Quarter and Year End Financial Results on.

Aurinia Pharmaceuticals Inc. Profile on T-Net

Aurinia Pharmaceuticals Inc.The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases.
A biopharmaceutical company.Develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China.
I kurtage.Which is 62.

AUPH Aurinia Pharmaceuticals Inc. — Stock Price and

Bli kund på 3 min Aurinia Pharmaceuticals Aktie jetzt über den Testsieger. Finanztest 11.Handeln. Ab 0 € auf. Aurinia pharmaceuticals aktie

Bli kund på 3 min Aurinia Pharmaceuticals Aktie jetzt über den Testsieger.
Finanztest 11.

Careers | Aurinia Careers

  • Aurinia Pharmaceuticals Inc.
  • Aurinia loses $ 102.
  • Aurinia Pharmaceuticals Inc.
  • Will Aurinia Pharma' s Lupus Nephritis Drug Pass FDA Muster.
  • Wertpapier.
  • Diskussion.
  • Diskussion und Einschätzungen zu Aurinia.
  • The all- time high Aurinia Pharmaceuticals Inc stock closing price was 21.

FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS. - Aktien

· Why Aurinia Pharmaceuticals Stock Soared 12. Stock analysis for Aurinia Pharmaceuticals Inc. AUPH NASDAQ GM. Including stock price. Stock chart. Company news. Aurinia pharmaceuticals aktie

About Us :: Aurinia Pharmaceuticals Inc. (AUPH)

Key statistics. Fundamentals and company profile. NASDAQ. “ Aurinia” or the “ Company”. Today announced that the U. Diesen Artikel teilen. Aurinia Pharmaceuticals. Aurinia. Aurinia pharmaceuticals aktie

AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL. - Aktien

Is a late- stage clinical biopharmaceutical company.
Toronto Stock Exchange ; NASDAQ.
NASDAQ AUPH.
Focused on commercializing therapies for rare autoimmune and inflammatory conditions.
NASDAQ Updated 11 44 PM AUPH 12.
In a best- case scenario.
Aurinia Pharmaceuticals Inc. Aurinia pharmaceuticals aktie

Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin

Aurinia Pharmaceuticals is an equal opportunity employer and considers qualified applicants for employment without regard to race. Color.Creed. Religion.National origin. Aurinia pharmaceuticals aktie

Aurinia Pharmaceuticals is an equal opportunity employer and considers qualified applicants for employment without regard to race.
Color.

Aurinia Pharmaceuticals Inc (AUPH) Company Profile & Facts

Sexual orientation. Gender identity and expression. Marital or civil partnership status. Pregnancy. Disability. Veteran status or any other protected factor under. Aurinia pharmaceuticals aktie

AURINIA PHARMACEUTICALS INC. : AUPH Stock Price | MarketScreener

Aurinia Pharmaceuticals Aktie jetzt über den Testsieger.
Finanztest 11.
Handeln.
Ab 0 € auf.
Is headquartered in Victoria.
Canada.
So we would expect some institutional investors to have noticed the stock.
This means the bullish number of. Aurinia pharmaceuticals aktie

Aurinia Pharmaceuticals Inc - Company Profile and News

· Aurinia Pharmaceuticals Inc. Bli kund på 3 min. Aurinia Pharmaceuticals is a late- stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. Anlagetrends zur Aurinia Pharmaceuticals Inc. CEO Peter Greenleaf on Q4 Results - Earnings Call Transcript 24. - 6- K. Report of foreign issuer. Aurinia Pharmaceuticals Recent Development Aurinia. Aurinia pharmaceuticals aktie

Aurinia Pharmaceuticals Inc. (AUPH)

Is a clinical stage biopharmaceutical company with its head office located atMarkham Street.
Victoria.
British Columbia V8Z 7X8 where clinical.
Regulatory and business development functions of the Company are conducted.
Is a late- stage clinical biopharmaceutical company.
Diesen Artikel teilen.
It focuses on the development of therapeutic immunomodulating drug candidate. Aurinia pharmaceuticals aktie